DOAJ (DOAJ: Directory of Open Access Journals) · 2022 · 21 citations · 30 references
Open access
MedicineImmunologyOncologyImmunotherapyMolecular OncologyTumor MicroenvironmentCancer BiomarkersCancer ImmunotherapyCancer Survival AnalysisCancer TranscriptomicsImmune Checkpoint InhibitorsTranscriptomic ProfilingCheckpoint Inhibitor Response PredictionGlioblastoma ImmunotherapyGlioblastoma PrognosisImmune Microenvironment PrognosisPredictive Biomarker DiscoveryPrognostic Expression SignaturesPrognostic PredictionPrognostic Prediction Models
Jianglin Zheng,1,* Zijie Zhou,1,* Yue Qiu,2,* Minjie Wang,1 Hao Yu,1 Zhipeng Wu,1 Xuan Wang,1 Xiaobing Jiang1 1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xuan Wang; Xiaobing JiangDepartment of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of ChinaEmail highprefer@126.com; 2004xh0835@hust.edu.cnPurpose: As an inflammatory form of programmed cell death, pyroptosis has been well established to be associated with tumorigenesis and tumor immune microenvironment. In this paper, we aimed at the construction of a pyroptosis-related gene prognostic index (PRGPI) for predicting prognosis and guiding individualized immunotherapy in glioma patients.Patients and Methods: Pyroptosis-related genes (PRGs) were identified based on a detailed review of published literatures. The transcriptome data and clinical information of glioma patients were obtained from CGGA and TCGA databases. PRGPI was constructed by using the multivariate Cox regression method. The immune cell infiltration level was analyzed via CIBERSORT algorithm. The tumor immune dysfunction and exclusion (TIDE) algorithm was applied to evaluate the potential response to immune checkpoint inhibitor (ICI) therapy. The expression patterns of PRGs in PRGPI were validated in cell lines and pathological specimens.Results: We identified a total of 31 PRGs. Among them, PRGs (CASP3, DPP9, MAPK8, PELP1 and TOMM20) were selected for the construction of PRGPI. In both training (CGGA693) and validation (CGGA325 and TCGA) cohorts, PRGPI-high patients showed an inferior survival outcome compared with PRGPI-low patients. ROC curves illustrated that the prognostic prediction power of PRGPI was robust. A nomogram was developed based on independent prognostic indicators (PRGPI, age and WHO grade), and also exhibited a strong forecasting ability for overall survival (OS). Additionally, PRGPI-high patients exhibited higher immune, stroma and ESTIMATE scores, lower tumor purity, higher infiltration of M2-type macrophages, lower infiltration of CD8+ T cells and activated NK cells, higher tumor mutation burden (TMB), and higher expression of immune checkpoints. TIDE showed that PRGPI-high group had more responders of ICI therapy than PRGPI-low group. Finally, the expression patterns of five selected PRGs in PRGPI were significantly different between normal and glioma.Conclusion: The constructed PRGPI can be used for predicting prognosis and guiding individualized immunotherapy in glioma patients.Keywords: pyroptosis, glioma, prognosis, immune microenvironment, ICI therapy
30
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman, Chih Long Liu, Michael R. Green et al. · Nature Methods · 2015 · 14.1K citations · Full text
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang, Shengqing Gu, Deng Pan et al. · Nature Medicine · 2018 · 5.6K citations · Full text
Life Sciences, Immunology, Oncology +14